414 related articles for article (PubMed ID: 19734480)
1. Primary lymphoma of bone: extranodal lymphoma with favourable survival independent of germinal centre, post-germinal centre or indeterminate phenotype.
Heyning FH; Hogendoorn PC; Kramer MH; Holland CT; Dreef E; Jansen PM
J Clin Pathol; 2009 Sep; 62(9):820-4. PubMed ID: 19734480
[TBL] [Abstract][Full Text] [Related]
2. Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas.
Paik JH; Jeon YK; Park SS; Kim YA; Kim JE; Huh J; Lee SS; Kim WH; Kim CW
Histopathology; 2005 Sep; 47(3):281-91. PubMed ID: 16115229
[TBL] [Abstract][Full Text] [Related]
3. Gastric and intestinal diffuse large B-cell lymphomas are clinically and immunophenotypically different. An immunohistochemical and clinical study.
Connor J; Ashton-Key M
Histopathology; 2007 Nov; 51(5):697-703. PubMed ID: 17927592
[TBL] [Abstract][Full Text] [Related]
4. Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients.
Amen F; Horncastle D; Elderfield K; Banham AH; Bower M; Macdonald D; Kanfer E; Naresh KN
Histopathology; 2007 Jul; 51(1):70-9. PubMed ID: 17593082
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma.
Pedersen LM; Jürgensen GW; Johnsen HE
Br J Haematol; 2005 Mar; 128(6):813-9. PubMed ID: 15755285
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
[TBL] [Abstract][Full Text] [Related]
8. Outcome and prognostic factors in ocular adnexal lymphoma.
Nola M; Lukenda A; Bollmann M; Kalauz M; Petrovecki M; Bollmann R
Croat Med J; 2004 Jun; 45(3):328-32. PubMed ID: 15185428
[TBL] [Abstract][Full Text] [Related]
9. SHP-1 expression in primary central nervous system B-cell lymphomas in immunocompetent patients reflects maturation stage of normal B cell counterparts.
Sugita Y; Tokunaga O; Nakashima A; Shigemori M
Pathol Int; 2004 Sep; 54(9):659-66. PubMed ID: 15363033
[TBL] [Abstract][Full Text] [Related]
10. Primary diffuse large B-cell lymphomas of the bone: prognostic relevance of protein expression and clinical factors.
Adams H; Tzankov A; d'Hondt S; Jundt G; Dirnhofer S; Went P
Hum Pathol; 2008 Sep; 39(9):1323-30. PubMed ID: 18614198
[TBL] [Abstract][Full Text] [Related]
11. Perforation predicts poor prognosis in patients with primary intestinal diffuse large B-cell lymphoma.
Chuang SS; Ye H; Yang SF; Huang WT; Chen HK; Hsieh PP; Hwang WS; Chang KY; Lu CL; Du MQ
Histopathology; 2008 Oct; 53(4):432-40. PubMed ID: 18983608
[TBL] [Abstract][Full Text] [Related]
12. Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients.
Beal K; Allen L; Yahalom J
Cancer; 2006 Jun; 106(12):2652-6. PubMed ID: 16700039
[TBL] [Abstract][Full Text] [Related]
13. Pathogenetic and clinical implications of Bcl-6 and Bcl-2 gene configuration in nodal diffuse large B-cell lymphomas.
Pescarmona E; De Sanctis V; Pistilli A; Pacchiarotti A; Martelli M; Guglielmi C; Mandelli F; Baroni CD; Le Coco F
J Pathol; 1997 Nov; 183(3):281-6. PubMed ID: 9422982
[TBL] [Abstract][Full Text] [Related]
14. Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma.
Nyman H; Jantunen E; Juvonen E; Elonen E; Böhm J; Kosma VM; Enblad G; Karjalainen-Lindsberg ML; Leppä S
Bone Marrow Transplant; 2008 Jul; 42(2):93-8. PubMed ID: 18391989
[TBL] [Abstract][Full Text] [Related]
15. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.
López-Guillermo A; Colomo L; Jiménez M; Bosch F; Villamor N; Arenillas L; Muntañola A; Montoto S; Giné E; Colomer D; Beà S; Campo E; Montserrat E
J Clin Oncol; 2005 Apr; 23(12):2797-804. PubMed ID: 15728226
[TBL] [Abstract][Full Text] [Related]
16. Diffuse large B-cell lymphoma of bone: an analysis of differentiation-associated antigens with clinical correlation.
de Leval L; Braaten KM; Ancukiewicz M; Kiggundu E; Delaney T; Mankin HJ; Harris NL
Am J Surg Pathol; 2003 Sep; 27(9):1269-77. PubMed ID: 12960812
[TBL] [Abstract][Full Text] [Related]
17. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays.
Zinzani PL; Dirnhofer S; Sabattini E; Alinari L; Piccaluga PP; Stefoni V; Tani M; Musuraca G; Marchi E; Falini B; Baccarani M; Pileri SA
Haematologica; 2005 Mar; 90(3):341-7. PubMed ID: 15749666
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2.
Xu Y; McKenna RW; Molberg KH; Kroft SH
Am J Clin Pathol; 2001 Aug; 116(2):183-90. PubMed ID: 11488064
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients.
Liu YH; Xu FP; Zhuang HG; Lai KC; Xie D; Luo DL; Li L; Luo XL; Xu J; Zhang MH; Zhang F; Li HM
Hum Pathol; 2008 Jun; 39(6):875-84. PubMed ID: 18440593
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma.
Eser B; Sari I; Canoz O; Altuntas F; Cakmak E; Ozturk A; Ozkan M; Er O; Cetin M; Unal A
Am J Hematol; 2006 May; 81(5):307-14. PubMed ID: 16628716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
